Medical Devices; Neurological Devices; Classification of the Prognostic Assessment Software of Mild Cognitive Impairment
Key claim: The Food and Drug Administration has officially classified mild cognitive impairment prognostic assessment software as a Class II medical device subject to special controls, creating a standardized pathway for market clearance.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the prognostic assessment software of mild cognitive impairment into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the prognostic assessment software of mild cognitive impairment. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
This final rule establishes a Class II regulatory framework with special controls for mild cognitive impairment prognostic assessment software, defining requirements for manufacturers seeking market clearance. For patients and providers, it sets regulatory standards for this category of prognostic tool; the classification does not itself establish insurance coverage or change patient cost-sharing.